Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

Patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplantation (ASCT) have lower survival rates and may benefit from frontline regimens that include novel agents. This Phase 1b study (NCT02513186) evaluated preliminary efficacy, safety, and pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales: Ocio, Enrique M., Perrot, Aurore, Bories, Pierre, San-Miguel, Jesus F., Blau, Igor W., Karlin, Lionel, Martinez-Lopez, Joaquin, Wang, Song-Yau, Bringhen, Sara, Marcatti, Magda, Mateos, María-Victoria, Rodriguez-Otero, Paula, Oliva, Stefania, Nogai, Axel, Le Roux, Nadia, Dong, Liyan, Macé, Sandrine, Gassiot, Matthieu, Fitzmaurice, Thomas, Oprea, Corina, Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264885/
https://www.ncbi.nlm.nih.gov/pubmed/37316728
http://dx.doi.org/10.1038/s41375-023-01936-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264885/
https://www.ncbi.nlm.nih.gov/pubmed/37316728
http://dx.doi.org/10.1038/s41375-023-01936-7

Ejemplares similares